Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a studyVolkan Granit, Matthew T. Duvernay, Nizar Chahin et al.|The Lancet Neurology|2023Cited by 255
Safety and Tolerability of BCMA-Directed mRNA CAR T-Cell Therapy in Multiple Myeloma and Autoimmune DiseaseMiloš D. Miljković, Metin Kurtoğlu, Adam S. Asch et al.|Blood|2024Cited by 6